Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib versus standard of care as first-line treatment for RET fusion-positive metastatic non-small cell lung cancer
NL-OMON49533Phase 3Recruiting
- Sponsor
- Blueprint Medicines
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pralsetinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Blueprint Medicines. Primary endpoint: Progression-free survival. Started Apr 2021; status: recruiting.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49533.